Yamirka Duardo-Guerra
Family Medicine · Miami, FLNPI 1295935047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $150 of the $188 with a category attached, or 79.8%. Galderma Laboratories, L.p. accounts for 79.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $150 and has fallen 89.2% since, to $16 in 2024. That places this record below the midpoint for family medicine clinicians in FL, where the typical reported total is $424.
Across 3 payments — averaging $62.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$150
- Pfizer$22
- Phadia US Inc.$16
Across 527 payments — averaging $8109.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Celltrion, Inc.$614K
- Sumitomo Pharma America, Inc.$506K
- First Wave Biopharma, Inc.$383K
- GSK$270K
- E.r. Squibb & Sons, L.L.C.$240K
- plus $635K from 15 others
What the payments were for
- Speaking & faculty fees$15080%
- Food & beverage$3820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 1 | $150 |
| Pfizer | 1 | $22 |
| Phadia US Inc. | 1 | $16 |
How this compares
$188 in reported general payments places this provider in the 30th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $73,137 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 63 | $54,279 |
| JardianceEmpagliflozin | 24 | $28,073 |
| JanuviaSitagliptin Phosphate | 32 | $22,820 |
| XareltoRivaroxaban | 16 | $18,338 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $17,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,448 |
| Diclofenac Sodium | 247 | $8,413 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,566 |
| Famotidine | 286 | $4,308 |
| Galantamine ErGalantamine Hbr | 26 | $4,128 |
| Rosuvastatin Calcium | 422 | $3,907 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,539 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $2,483 |
| Mirtazapine | 76 | $2,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $73,13778 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.